FIH

Laplace Interventional Inc. Announces first close of an Oversubscribed Series B Financing of $12.9M for its Transcatheter Tricuspid Valve Technology

Retrieved on: 
Tuesday, July 25, 2023

MINNEAPOLIS, July 24, 2023 /PRNewswire/ -- Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has completed its first close on its Series B financing co-led by ShangBay Capital along with Features Capital, including participation from Engage Venture Partners, JWC Ventures as well as a global strategic investor. The $12.9M Series B financing will fund Laplace Interventional towards achieving its early clinical feasibility milestones. The company also announced that Jenny Barba, Co-Founder and Managing Partner at Features Capital, joined its Board of Directors and Todd Mortier, a serial MedTech entrepreneur had previously joined its Board of Directors.

Key Points: 
  • Laplace Interventional plans to use the funds raised from this round to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.
  • The $12.9M Series B financing will fund Laplace Interventional towards achieving its early clinical feasibility milestones.
  • Laplace Interventional's device is designed to offer an increase in life expectancy and an improvement to the quality of life to patients diagnosed with Tricuspid Regurgitation (TR).
  • Laplace Interventional is developing a prosthetic valve that will be delivered through through patient vasculature not requiring an open-heart surgery and thereby reducing complications in patients.

Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis

Retrieved on: 
Friday, July 21, 2023

Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug’s release.

Key Points: 
  • Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug’s release.
  • The administration of oral medication is generally regarded as the preferred method for patients with UC due to its safety, pain avoidance and patient compliance.
  • Triastek developed T21 in an effort to solve the problem of targeted and precise delivery of oral drugs to the gastrointestinal tract.
  • Triastek aims to develop partnerships with pharmaceutical companies to help it differentiate its products through the use of 3D printing of medicines.

Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services

Retrieved on: 
Friday, July 7, 2023

In a momentous event held in May 2023, Dr. Zhen Liu, Head of CMC at Allorion Therapeutics, presented the prestigious "Best Partner" commemorative trophies to Crystal Pharmatech's CRO and CDMO Business Units (Crystal Formulation Services, CFS).

Key Points: 
  • In a momentous event held in May 2023, Dr. Zhen Liu, Head of CMC at Allorion Therapeutics, presented the prestigious "Best Partner" commemorative trophies to Crystal Pharmatech's CRO and CDMO Business Units (Crystal Formulation Services, CFS).
  • With a proactive approach to collaboration, Crystal Pharmatech has finely managed projects, ensuring their smooth progression and delivering high-quality results in a timely manner.
  • Dr. Decheng Ma, CEO of Crystal Formulation Services, expressed appreciation for being recognized by Allorion Therapeutics, CFS's first strategic partner, "we are extremely honored to receive Allorion's recognition and be bestowed with the title of 'Best Partner.'
  • Dr. Alex Chen, CEO of Crystal Pharmatech, commented, "As a cutting-edge precision medicine drug development company, Allorion Therapeutics boasts an internationally renowned leadership team and operates at the forefront of global innovation.

Propanc Biopharma Provides Shareholder Update

Retrieved on: 
Thursday, June 22, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.
  • Propanc recently filed a post-effective Form S-1 amendment on behalf the lead investor who has funded approximately $2.25 million to date.
  • Propanc plans to compile the Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in 2023.
  • To date, Propanc has raised approximately $23 million dollars, culminating in the Company’s lead asset ready to commence clinical development, and a backup clinical compound entering preclinical stage.

GreenFields Pure EP is the first certified Dry (non-irrigated) hockey turf

Retrieved on: 
Monday, June 19, 2023

With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.

Key Points: 
  • With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.
  • Field hockey players say the new dry (non-irrigated) hockey turf rivals the quality of water-based artificial turf, while saving millions of litres of (drinking) water per year.
  • Field hockey club MHC Weesp is the proud owner of the world's first dry (non-irrigated) hockey turf field.
  • Furthermore, Pure EP will create a level playing field in the international world of field hockey.

GreenFields Pure EP is the first certified Dry (non-irrigated) hockey turf

Retrieved on: 
Monday, June 19, 2023

With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.

Key Points: 
  • With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.
  • Field hockey players say the new dry (non-irrigated) hockey turf rivals the quality of water-based artificial turf, while saving millions of litres of (drinking) water per year.
  • Field hockey club MHC Weesp is the proud owner of the world's first dry (non-irrigated) hockey turf field.
  • Furthermore, Pure EP will create a level playing field in the international world of field hockey.

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

Retrieved on: 
Friday, June 16, 2023

Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Key Points: 
  • Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
  • In addition, one of the abstracts was accepted as an oral presentation.
  • These peer-reviewed abstracts follow the highly successful extended joint pre-clinical animal studies held at leading European-based research labs by a team of seven renowned European interventional radiologists.
  • We believe that the current and future peer-reviewed data will accelerate adoption of LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

Propanc Biopharma Announces Strategic Pharma Partnering Initiative

Retrieved on: 
Tuesday, June 6, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering initiative, as its lead product candidate, PRP, advances towards a Phase I, First-In-Human (FIH) study in advanced cancer patients.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering initiative, as its lead product candidate, PRP, advances towards a Phase I, First-In-Human (FIH) study in advanced cancer patients.
  • Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clinical development and for future commercialization.
  • The strategic goal of these potential collaborations is to develop and commercialize PRP for the treatment and prevention of metastatic cancer from solid tumors in major pharmaceutical markets worldwide.
  • Several other major companies were approached and Propanc expects to resume discussions during the next stage of clinical development for PRP.

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Retrieved on: 
Monday, June 5, 2023

The FIH trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of CSF biomarkers) and immunogenicity of RAG-17 in ALS patients with a confirmed SOD-1 mutation.

Key Points: 
  • The FIH trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of CSF biomarkers) and immunogenicity of RAG-17 in ALS patients with a confirmed SOD-1 mutation.
  • "We are extremely pleased to initiate this first in human trial of RAG-17, marking our transformation into a clinical-stage company" said Dr. Long-Cheng Li, Ractigen’s Founder, President and Chief Executive Officer.
  • "This milestone highlights our commitment to building and strengthening our pipeline and clinical validation of our novel CNS delivery platform.
  • Given our mission to deliver innovative medicines to patients with high, unmet needs, we look forward to continued enrolment and dosing of patients in this trial" added Dr. Li.

Myrtelle to Present Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference

Retrieved on: 
Wednesday, May 31, 2023

Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.

Key Points: 
  • Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients in Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • “Connecting with patients and caregivers allows us to incorporate the patient voice into our drug development activities.”